AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05104801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: tislelizumab 200mg Q3W IV
Study NCT04707703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazonium Injection [Cresemba]
Description: Intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by intravenous isavuconazonium sulfate 372 mg once daily for up to 28 days
Study NCT04707703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo every 8 hours for 6 doses followed by intravenous placebo once daily for up to 28 days
Study NCT04702880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012
Description: Specified dose on specified days
Study NCT04702880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT04702880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Specified dose on specified days
Study NCT04702880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT05688098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irbesartan/Amlodipine High FDC
Description: Irbesartan/Amlodipine High FDC
Study NCT05688098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irbesartan
Description: Co-administration of Irbesartan and Amlodipine High
Study NCT04729179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Participants will start with 10 mg of cannabidiol daily and the dose will be escalated every third day until the maximum dosage of 50 mg is reached (after two weeks). The participants be on the 50 mg dosage of cannabidiol for 24 weeks.
Study NCT04729179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.
Study NCT06125743 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Participants will conduct self-care activities prescribed by their treating lymphedema therapists.
Study NCT06125743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person LEF-SMP
Description: Participants will receive the in-person LEF-SMP intervention.
Study NCT06125743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth LEF-SMP
Description: Participants will receive the telehealth LEF-SMP intervention.
Study NCT06445387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: Preparation Stage of Virtual Glasses: A 20-minute video consisting of nature scenes shot with a 360-degree camera was selected by the researchers from YouTube. Permission was obtained from the person who created the video.~For the selection of music, both the music that is good for diseases were examined in the literature and an expert opinion was taken from a faculty member (Phd, assistant professor) working at the Faculty of Music and Fine Arts of a university. The music used in the video was created with works selected from the Hüseyni maqam.
Study NCT06445387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Application Group
Description: Features of the ice and ice bag used for patients in ice application; Ice cubes with dimensions of 9.5 x 26 x 3.5 cm were used. The ice bag is made of cotton and polyester coated fabric and is easily bendable. In this way, the ice bag was ensured to fit properly to the patient's femoral region. It is reusable and heat insulated. The procedure was carried out by following the cold application step protocol created by the researchers using the literature.
Study NCT06445387 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: They continued to receive their routine treatment and care. No changes were made in their routine treatment and care.
Study NCT04861870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MenCare+/Bandebereho fathers'/couples' group education
Description: MenCare+/Bandebereho was a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engaged men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focused on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
Study NCT05310201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be Well Care Well
Description: Be Well Care Well addresses teacher well-being through activities implemented in the classroom aimed at reducing teacher stress and improving physical activity. A subset of teachers involved in the program will complete classroom observations and cortisol testing to examine additional measures of stress.
Study NCT05250713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial stimulation
Description: Patients will receive either direct current stimulation or alternate stimulation.
Study NCT04661475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: ECT and anaesthetic treatment protocols will be determined by the local ECT services. ECT being given twice a week. The anesthetic induction agent of choice will usually be propofol, with thiopental permissible as an alternative. For safety reasons, any drug contraindicated to be given with DEX will be avoided. Especially the once known to decrease arterial pressure and heart rate excessively. Oral psychotropic medication to be continued by the patient's treating clinical team will remain unchanged where possible for at least the first 4 ECT treatments, and ideally until end of ECT. Eligible subjects will be allocated randomly to receive either 0.5µg/kg dexmedetomidine add on (diluted to 10 ml with 0.9% saline) at a steady rate of 1 ml/min, for 10 min.Participants in the two groups will receive DEX or Saline adjunct thrice weekly for 3 weeks.
Study NCT04661475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: while patients in the Control group will be infused with 10 ml of 0.9% saline at the same rate, over 10 minutes before anesthesia induction for ECT procedure.
Study NCT05461105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rencofilstat, 75 mg
Description: 1 softgel capsule
Study NCT05461105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rencofilstat, 150mg
Description: 2 softgel capsules
Study NCT05461105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rencofilstat, 225 mg
Description: 3 softgel capsules
Study NCT05430048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal Desmopressin
Description: compare the effect of nasal desmopressin versus oral bisoprolol for controlling bleeding and improving surgical field clarity during functional endoscopic sinus surgery.
Study NCT05697549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior language therapy
Description: Cognitive behavior language therapy is an extensive form of Cognitive behavior therapy. and it is used in the management of speech-language related problems. It helps the individuals to change their unhelpful thoughts and beliefs that cause difficulty for them to communicate properly and effectively. and it also helps the individuals to use their remaining language abilities, to restore their language abilities and to learn the other ways of communication i.e. pointing, gesturing and Augmentative alternative communication.
Study NCT05449886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVC
Description: Tidal volume challenge from 6ml/kg to 10ml/kg for 1 min.
Study NCT05591625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitisation and Reprocessing
Description: EMDR is a trauma-focussed, psychological talking therapy whereby the participant verbally relates a narrative of an emotionally disturbing memory, in brief sequential doses, while simultaneously focusing on an external stimulus, most commonly side-to-side finger movements of the psychological therapist. EMDR aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR is widely practiced, so is scalable. It is also protocolised, so can be taught and tested, and allows for fidelity assessment in controlled studies.~The number of sessions will depend on ongoing presence of disturbing memories. This will be determined by the psychological therapist and participant.
Study NCT05145842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: floroscopy
Description: After proper antiseptic dressing and draping, sacral hiatus was identified. the position of the needle was confirmed by lateral and anteroposterior fluoroscopic images. The needle was introduced up to S3 level for proper spread of the drug.
Study NCT05145842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound+fluoroscopy
Description: After proper antiseptic dressing and draping, the caudal region will be shown in the longitudinal section using sterile probe cover and gel. Under ultrasonographic imaging, the sacrococcygeal ligament will be crossed and the needle will not be advanced any further once the sacral canal is entered. The fluoroscopy phase of the combined imaging will be started and the needle position will be checked by taking an anteroposterior view. The needle tip will be positioned at the sacral 3 level. The needle will be repositioned until the proper position is achieved. The research will be terminated at this point and the time to this stage and the radiation exposure dose will be obtained.
Study NCT05439239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated sprint training
Description: Participants will perform 7 weeks of cycling repeated sprint training (2x/week). Inspired oxygen fraction (FiO2) will be set to 14.6% and 20.9% for the hypoxic and normoxic group to simulate an altitude of 3000 m and 300 m, respectively.~The training sessions will consist of a 10-min warm up followed by 3 sets of 5 x 10-s all-out repeated sprints on the cycle ergometer. The number of sets will decrease to two during week 7. Participants will be instructed to try to reach and maintain maximal power output during each sprint. An active recovery at 30% of VO2max will be allowed for 20 s between sprints and for 5 min between sets. The training will end with a 10-min cool down at 30% VO2max. An individual fixed torque of 0.7 will be used during the sprints and it will be reduced to 0.5 Nm/kg at week 7.
Study NCT05439239 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Repeated sprint training
Description: Participants will perform 7 weeks of cycling repeated sprint training (2x/week). Inspired oxygen fraction (FiO2) will be set to 14.6% and 20.9% for the hypoxic and normoxic group to simulate an altitude of 3000 m and 300 m, respectively.~The training sessions will consist of a 10-min warm up followed by 3 sets of 5 x 10-s all-out repeated sprints on the cycle ergometer. The number of sets will decrease to two during week 7. Participants will be instructed to try to reach and maintain maximal power output during each sprint. An active recovery at 30% of VO2max will be allowed for 20 s between sprints and for 5 min between sets. The training will end with a 10-min cool down at 30% VO2max. An individual fixed torque of 0.7 will be used during the sprints and it will be reduced to 0.5 Nm/kg at week 7.
Study NCT03669653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
Study NCT03669653 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days.
Study NCT05208853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti CD30 CAR-T Cell Injection
Description: After enrollment, subjects complete the apheresis, then complete the lymphodepletion, and then receive the dose escalation test: 1.5×10\^7 cells，1.5×10\^8 cells，5× 10\^8 cells.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion
Study NCT05174923 — intervention group
Intervention type: BEHAVIORAL
Intervention: Short Performance Physical Battery (SPPB Test)
Description: The SPPB includes balance stands, a 4-meter walk and 5 timed chair stands.
Study NCT05174923 — intervention group
Intervention type: BEHAVIORAL
Intervention: 30 Second Chair Stand Test (30CST)
Description: The 30CST measures the number of times a person can rise from a seated to standing position within 30 seconds.
Study NCT05174923 — intervention group
Intervention type: BEHAVIORAL
Intervention: Hand grip dynamometry
Description: Grip strength is used as a marker of overall muscle strength.
Study NCT06280495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 5 mg/m2 IV on day 1
Study NCT06280495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 5 mg/m2 IV on day 1
Study NCT06280495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 400 mg/m2 IV bolus on day 1, followed by 2.4 g/m2 continuous IV infusion over 48 hours
Study NCT06280495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400 mg/m2 IV bolus on day 1, followed by 2.4 g/m2 continuous IV infusion over 48 hours
Study NCT06280495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: 200 mg IV infusion on day 1
Study NCT06280495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg IV infusion on day 1
Study NCT04762225 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPTR-168
Description: Escalating doses of RPTR-168 as a monotherapy
Study NCT05309538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified eply & Semont maneuver
Description: repositioning maneauvers
Study NCT05309538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: betahistine & Modified eply & Semont maneuver
Description: antihistamine plus repositioning maneuvers
Study NCT06428461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular brachial plexus block
Description: A supraclavicular brachial plexus block will be performed under ultrasound guidance. The patient will be taken to the preoperative block room, positioned supine with the bed elevated at a 30° angle, and the head turned away from the arm being blocked. To avoid intraneural injection, the block will use both ultrasound and a nerve stimulator (Plexygon, Vygon-Italy) with a 22G 50 mm 20° stimulating needle (Echoplex, Braun-France). A low-frequency ultrasound probe will be placed above the clavicle to visualize the subclavian artery and vein. Using an in-plane approach, the needle will be inserted laterally to medially from the mid-clavicular point through the skin and subcutaneous tissue. Under ultrasound guidance, the needle will be advanced towards the anatomical corner where the brachial plexus and subclavian artery are adjacent (corner pocket), and a local anesthetic agent will be injected to perform the block.
Study NCT06428461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of Optic Nerve Sheath Diameter (ONSD) Using B-Mode Ultrasound
Description: Before the block, both eyes will be measured for optic nerve sheath diameter (ONSD) using B-mode ultrasound (USG) with a GE LOGIQ E device. The patient will be supine with the bed elevated at a 30° angle, eyes closed, and a protective barrier applied. Both globes will be filled with water-soluble ultrasound gel, and imaging will be done with a 7.5 MHz linear probe at a 7 cm depth. For transverse ONSD measurement, the probe will be placed transversely in the coronal plane, with the marker notch pointing right. When the optic nerve entry into the globe is clear, transverse ONSD will be measured 3 mm below. For sagittal measurement, the probe will be placed sagittally in the coronal plane, with the marker notch pointing towards the body. Sagittal ONSD will be measured 3 mm below the entry point. Both internal and external diameters of the optic nerve sheath will be measured in transverse and sagittal planes, and the transverse diameter of the globe will also be measured.
Study NCT06428461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of Peripheral Nerve Block Success Using Perfusion Index Measurement
Description: Investigator plan to measure the Perfusion Index (PI) as an objective method for determining the success of peripheral nerve blocks, different from traditional tests. PI is an indicator of peripheral perfusion that can be continuously measured non-invasively with a pulse oximeter. PI represents the ratio of pulsatile blood flow to non-pulsatile blood flow in peripheral tissue. The Mindray uMEC 12 device will be used for this measurement.
Study NCT06428461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: End-Tidal Carbon Dioxide (EtCO2) Measurement
Description: End-tidal carbon dioxide (EtCO2) measurement: The Medtronic Capnostream 35 device will be used for EtCO2 measurements. All patients will receive oxygen support at a rate of 1-2 L/min. If peripheral oxygen saturation falls below 95%, oxygen support will be increased to 3-6 L/min via nasal cannula.
Study NCT06037174 — intervention group
Intervention type: PROCEDURE
Intervention: minimally invasive procedure
Description: different minimally invasive approach to complete thyroidectomy, including endoscopy-assisted subclavian approach, robot-assisted transaxillary or transoral approach (not leaving scar on the neck)
Study NCT06037174 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional Open Surgery
Description: Conventional Open Surgery
Study NCT06257355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSB-001 Ophthalmic Solution 0.1%
Description: CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
Study NCT03529448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TN-TC11G
Description: TN-TC11G dose will be gradually increased as follows:~Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).~Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered.
Study NCT03529448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Oral Product
Description: During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.~At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles.
Study NCT03529448 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All the patients will receive the Stupp regimen. The radiotherapy (RT) treatment will be administered in fractions of 1.8-2.0 Gy/day delivered 5 days/week to a total dose of 58-60 Gy. Radiotherapy will be delivered to the gross tumor volume with a 2-3 cm margin for the clinical target volume.
Study NCT05084222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buventol® Easyhaler® 200 µg/inhalation dmDPI
Description: Two doses will be administered
Study NCT05084222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI
Description: Two doses will be administered
Study NCT05084222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ventoline® Evohaler® 100 µg/inhalation pMDI
Description: Four doses will be administered via Volumatic spacer
Study NCT05688098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine High
Description: Co-administration of Irbesartan and Amlodipine High
Study NCT06196125 — intervention group
Intervention type: OTHER
Intervention: Four body positions
Description: Physiological characteristics such as ventilation distribution and lung aeration patterns recorded by the electrical impedance tomography signals and ultrasound imaging will be measured when patients are in a initial supine position, then turned into a lateral positioning on each side then back in supine positioning.
Study NCT04284839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOAC
Description: Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
Study NCT04284839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VKA
Description: Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.